

Immune Globulin (Ig) for Measles Post-Exposure Prophylaxis: Resources for Clinicians

Indications:

- Measles post-exposure prophylaxis (PEP) can include the administration of immune globulin (Ig) for certain individuals at high-risk of measles complications. This can include:
 - Those with a contraindication (e.g., anaphylaxis) to the measles vaccine
 - Infants under six months of age
 - Individuals who are immunocompromised
 - Pregnant women
 - Infants 6-12 months of age, where the window for vaccine PEP has passed
- Intramuscular immunoglobulin (IMlg) or intravenous immunoglobulin (IVIg) may provide some protection or modify the clinical course of disease among susceptible contacts if administered within 6 days of exposure to a measles case

Products licensed for Measles Post-Exposure prophylaxis:

Intramuscular Immunoglobulin:

- GamaSTAN®

Intravenous Immunoglobulin:

- GAMMAGARD LIQUID®
- GAMMAGARD® S/D
- Gamunex®
- IGIVnex®
- OCTAGAM® 5%

More information found in Government of Canada, Table 6:

<https://rebrand.ly/measlesPEP>



PEP Guidance for high-risk populations:

Public Health Ontario has provided specific PEP recommendations for infants, susceptible pregnant contacts and contacts with immunocompromising conditions, including Ig dosages for those eligible for Ig PEP.

Table 1: Summary of Measles PEP Guidance for Susceptible Non-pregnant Immunocompetent Contacts

- Table 2: Summary of Measles PEP Guidance for Susceptible Pregnant Contacts

- Table 3: Summary of Measles PEP Guidance for Contacts with Immunocompromising Conditions.

<https://rebrand.ly/HighRiskGuidance>



IMiG Administration:

For IMiG administration guidelines, see British Columbia Centre for Diseases Control (BCCDC) guidance here:

<https://rebrand.ly/IMiG-admin>



Note: as per the National Advisory Committee on Immunization (NACI) and Public Health Ontario (PHO) IMiG is no longer recommended for persons ≥ 30 kg. All people requiring Ig PEP who weigh ≥ 30 kg should receive IVIg.